A carregar...
Phosphodiesterase type 5 inhibitor to riociguat transition is associated with hemodynamic and symptomatic improvement in pulmonary hypertension
Riociguat is a soluble guanylate cyclase stimulator approved for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. We studied the clinical and hemodynamics effects of transitioning 12 pulmonary hypertension patients from Phosphodiesterase type 5 inhi...
Na minha lista:
| Publicado no: | Pulm Circ |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5467945/ https://ncbi.nlm.nih.gov/pubmed/28597779 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2045893217708566 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|